LUCIUS 卢修斯 恩考芬尼 Encorafenib黑色素瘤

恩考芬尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Encorafenib

老挝国家食药监局批准上市
老挝国家药检所检测认证

omposition:

Each capsule contains Encorafenib ....... 75mg.

LUCIUS

75mg

黑色素瘤

Indication:
LuciEncor is a kinase inhibitor indicated, in

PHARMACEUTICALS

combination with Binimetinib, for the
treatment of patients with unresectable or
metastatic melanoma with a BRAF V600E o
V600K mutation, as detected by an FDA.
Dosage and Us

LuciEncor

*Confirm the presence of BRAF V600E or
V600K mutation in tumor specimens prior to
the initiation of LuciEncor.

Encorafenib Capsules

FDA批准

* The recommended dose is 450 mg orally
sierommen
once datly in combination with Binimetinib.
Take LuciEncor with or without food
Storage: in a dry place and store at 20℃1
25C.

Warning:

Keep medicine out of reach of Children. Do
not administer LuciEncor during Pregnancy
and Lactation
PLEASE SEE PACKAGE INSERT

权威认证

Manufactured and Marketed by:
LUCIUS

PHARNACEUTICALS
Thonemane vill
Thongmang village, Xaythany distric

Rx only

wwwlues

Warning: To be sold by retail on prescrintion

ered physicians onle and as doree
and as directed

90 Capsules

口碑质量

适应症:
恩考芬尼与比美替尼联合用于治疗经FDA批准的检测方

法检测为BRAF V600E或V600K突变的不可切除或转
移性黑色素瘤患者。
推荐剂量:
每日口服一次,每次450毫克,与比美替尼联合使用。可与
食物同服或单独服用。